Developer docs
API playgroundTry for free, no card

Search company profiles

Mirada Medical

Full company profile

uuid0002esf

Namestring
Mirada Medical
Legal namestring
Mirada Medical Limited
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Mirada Medical is an Oxford-headquartered medical imaging software company founded in 1999 that develops AI-enabled image registration, quantification, and treatment planning tools used in cancer diagnosis and therapy. Its product portfolio spans three specialty areas: Mirada XD for diagnostic PET/CT, PET/MR, and nuclear medicine reading; Mirada RTx and DLCExpert for radiation oncology image registration and AI-driven organ-at-risk auto-contouring (the first FDA-cleared AI of its kind globally); and Simplicit90Y for dosimetry planning in Y-90 selective internal radiation therapy. The technology stack combines deep learning-based contouring models, the proprietary RegEngine deformable image registration engine developed over more than 20 years, and a zero-click automation platform designed to plug directly into existing PACS and treatment planning systems.

Mirada generates revenue primarily through annual enterprise software licensing to hospitals and cancer centers, supplemented by OEM/embedded licensing royalties from major imaging and radiotherapy vendors (GE Healthcare, Canon, Philips, Varian, Boston Scientific) that distribute Mirada's technology within their own platforms. Distribution combines direct enterprise field sales in the UK and US with channel partnerships that broaden reach to over 2,000 hospitals globally. The company has secured two NHS AI in Health and Care Awards and a 2024 Innovate UK precision medicine grant, reflecting UK public-sector validation of its clinical evidence base.

The business is privately held and backed by healthcare-focused private equity firm Apposite Capital, which has invested approximately $20 million of growth capital since 2019 and holds a board seat. Mirada operates from Oxford, Denver, and Bordeaux, with a headcount in the 51-100 range. Recent strategic emphasis has shifted toward commercial scaling under a new CEO (Dr Karen Fitchett, 2024) and a newly appointed VP of Revenue, alongside expansion into PSMA PET/CT AI for prostate cancer and Dosimetry-as-a-Service offerings through the TeleDaas PLLC partnership.

Short descriptiontext

Mirada Medical is an Oxford-based, privately held medical imaging software company that develops FDA-cleared AI-enabled image registration, auto-contouring, and dosimetry tools sold to hospitals, cancer centers, and OEM imaging partners for cancer diagnosis and radiotherapy planning.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging software, radiation oncology software, AI autocontouring, diagnostic imaging solutions, image registration technology
Industry6 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAJ
Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Software Publishers5132
  • Software Publishers51321
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Imaging Software Licenses
TypeSubscription Recurring
Description

Mirada Medical generates revenue primarily through licensing its medical imaging software products including Mirada XD, Mirada RTx, DLCExpert, and Simplicit90Y. Products are sold directly to hospitals and through OEM partners who embed Mirada technology in their platforms.

mirada-medical.com
2OEM/Embedded Software Licensing
TypeLicensing Royalties
Description

Mirada provides its technology on an OEM basis to leading healthcare companies including GE, Canon, Philips, Varian, and Boston Scientific. These partnerships embed Mirada's software within partner platforms, generating licensing revenue.

mirada-medical.com
3Professional Services and Support
TypeProfessional Services
Description

The company provides customer success services including clinical onboarding, in-clinic deployment, and ongoing optimization support. Implementation and training services are part of the customer engagement model.

mirada-medical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise hospital licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for hospital deployments. Products include Mirada XD, RTx, DLCExpert, and Simplicit90Y with various licensing and deployment options including standalone workstation and thin client solutions.

mirada-medical.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Mirada XD
Description

Integrated vendor-neutral software for diagnostic reading of PET/CT, PET/MR, nuclear medicine, and image fusion.

mirada-medical.com
+4 more records
Core offering1 text field

Mirada Medical develops and licenses AI-powered medical imaging software for cancer care across three clinical specialties: diagnostic imaging (Mirada XD for PET/CT, PET/MR, and nuclear medicine reading), radiation oncology (Mirada RTx for image registration and visualization, DLCExpert for AI-powered organ-at-risk autocontouring), and interventional radiology (Simplicit90Y for Y-90 SIRT dosimetry planning). Products are sold directly to hospitals and cancer centers and embedded through OEM partnerships with GE Healthcare, Canon, Philips, Varian, and Boston Scientific.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 40-60% reduction in contouring time for H&N, breast, and pelvic disease sites
+4 more records
Product overview1 text field

Mirada Medical delivers a unified portfolio of medical imaging software for diagnosis, dosimetry, and image-guided cancer therapy across three specialties: diagnostic imaging, radiation oncology, and interventional radiology. The core product families are Mirada XD (diagnostic imaging software for PET/CT, PET/MR, and nuclear medicine reading), Mirada RTx (radiation oncology image registration and visualization platform), and Simplicit90Y (interventional dosimetry software for Y-90 SIRT). Key AI capabilities include DLCExpert for automated organ-at-risk contouring, RegEngine for deformable image registration, and zero-click automation platforms. Products are available under Mirada's own brand and on an OEM basis through partnerships with GE, Canon, Philips, Boston Scientific, Varian, and other leading healthcare companies. The software integrates with DICOM-compatible systems and PACS infrastructure across thousands of hospitals globally.

Product and service1 record
1Mirada XD
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-06-18
Description

Clinical partner for £500,000 Innovate UK grant to develop AI-assisted PSMA PET/CT solution for improved prostate cancer diagnosis.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-06-18
Description

Clinical partner collaborating on PSMA PET/CT AI solution development under Innovate UK Advancing Precision Medicine grant.

3University Hospitals Bristol and Weston NHS Foundation Trust
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-06-18
Description

Clinical partner for PSMA PET/CT AI-assisted solution research and development supporting widespread adoption of PSMA PET/CT in the clinic.

mirada-medical.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-11-26
Description

Dosimetry-as-a-Service medical practice using Mirada's proprietary software to support clinical research organizations in clinical trial design and development of new targeted radiation therapies.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2022-07-07
Description

Non-exclusive worldwide licensing agreement allowing integration of Mirada's RegEngine image registration algorithms into RefleXion X1 treatment planning software for biology-guided radiotherapy (BgRT).

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Global collaboration to improve outcomes for cancer patients by integrating Mirada's advanced automation and AI technologies to enable faster, more consistent and more precise cancer radiotherapy treatment. Mirada technology embedded in GE Healthcare ecosystem.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to develop and commercialize Simplicit90Y, a software product enabling personalization of dosimetry planning for TheraSphere, Boston Scientific's radiation-based cancer treatment using microscopic radioactive glass microspheres.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Mirada Oncology Fusion product offered through Canon, integrating Mirada's imaging software with Canon's healthcare IT platform for clinical applications.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Partnership integrating Mirada's imaging technology within Philips healthcare solutions. Mirada products available through Philips ecosystem for diagnostic imaging.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Mirada technology available through Varian's radiotherapy platform, enhancing treatment planning capabilities with Mirada's image registration and AI contouring.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership making Mirada technology available through Change Healthcare's imaging solutions and customer network.

12NCIMI (National Consortium of Intelligent Medical Imaging)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration with Leeds Teaching Hospitals and Alliance Medical Group investigating role of AI and Deep Learning in diagnostic nuclear medicine, particularly for lymphoma detection and reporting.

mirada-medical.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish developer of radiation therapy treatment planning software (RayStation) and oncology analytics. Direct competitor to Mirada RTx and DLCExpert, serving the same radiation oncology customer base with overlapping image registration and adaptive planning capabilities.

2MIM Software
TypeDirect peer
Description

US-based medical imaging software vendor offering multi-modality viewing, deformable registration, and AI-driven contouring (MIM Maestro). Closely comparable to Mirada's diagnostic imaging and radiation oncology workflows and customer base.

TypeDirect peer
Description

Private German company providing treatment planning, image-guided surgery and radiotherapy software (Elements). Directly competes with Mirada in radiation oncology planning and image registration, with overlapping hospital and cancer center customers.

TypeBroad incumbent
Description

Swedish listed vendor of linear accelerators and radiotherapy software (Mosaiq, Elekta ONE). A broader incumbent in radiation oncology that competes with and could substitute Mirada's planning and autocontouring capabilities as part of its integrated portfolio.

TypeBroad incumbent
Description

Global leader in radiation oncology treatment planning (Eclipse) and Ethos adaptive radiotherapy. Both an OEM partner of Mirada (Varian) and a potential substitute supplier, making it a strategic incumbent in the same category.

TypeBroad incumbent
Description

US-listed developer of CyberKnife and TomoTherapy radiation therapy systems with associated planning software. Broader incumbent serving overlapping radiation oncology customers and competing for the same hospital capital budgets.

TypeEmerging player
Description

US-based developer of biology-guided radiotherapy (BgRT) systems that licenses Mirada's RegEngine for its X1 platform. Emerging player in adaptive radiotherapy with a partial, partnership-based overlap to Mirada's image registration business.

TypeEmerging player
Description

Spanish AI imaging analytics company offering quantitative imaging biomarkers for oncology and radiology. Emerging AI-native vendor addressing similar PET/CT, MRI, and oncology quantification workflows as Mirada XD.

TypeOthers
Description

Global medical imaging equipment and healthcare IT vendor and an OEM partner of Mirada. Adjacent incumbent that both distributes Mirada's technology and develops its own AI imaging applications, making it a strategically dual customer-competitor.

TypeOthers
Description

Global healthcare technology vendor with diagnostic imaging, PACS, and oncology informatics offerings, and an OEM partner embedding Mirada's technology. Comparable as a broad incumbent and channel partner rather than a direct specialist competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mirada Medical

Medical Imaging Softwaremirada-medical.com

Mirada Medical is an Oxford-based, privately held medical imaging software company that develops FDA-cleared AI-enabled image registration, auto-contouring, and dosimetry tools sold to hospitals, cancer centers, and OEM imaging partners for cancer diagnosis and radiotherapy planning.

What Mirada Medical does

Mirada Medical is an Oxford-headquartered medical imaging software company founded in 1999 that develops AI-enabled image registration, quantification, and treatment planning tools used in cancer diagnosis and therapy. Its product portfolio spans three specialty areas: Mirada XD for diagnostic PET/CT, PET/MR, and nuclear medicine reading; Mirada RTx and DLCExpert for radiation oncology image registration and AI-driven organ-at-risk auto-contouring (the first FDA-cleared AI of its kind globally); and Simplicit90Y for dosimetry planning in Y-90 selective internal radiation therapy. The technology stack combines deep learning-based contouring models, the proprietary RegEngine deformable image registration engine developed over more than 20 years, and a zero-click automation platform designed to plug directly into existing PACS and treatment planning systems.

Mirada generates revenue primarily through annual enterprise software licensing to hospitals and cancer centers, supplemented by OEM/embedded licensing royalties from major imaging and radiotherapy vendors (GE Healthcare, Canon, Philips, Varian, Boston Scientific) that distribute Mirada's technology within their own platforms. Distribution combines direct enterprise field sales in the UK and US with channel partnerships that broaden reach to over 2,000 hospitals globally. The company has secured two NHS AI in Health and Care Awards and a 2024 Innovate UK precision medicine grant, reflecting UK public-sector validation of its clinical evidence base.

The business is privately held and backed by healthcare-focused private equity firm Apposite Capital, which has invested approximately $20 million of growth capital since 2019 and holds a board seat. Mirada operates from Oxford, Denver, and Bordeaux, with a headcount in the 51-100 range. Recent strategic emphasis has shifted toward commercial scaling under a new CEO (Dr Karen Fitchett, 2024) and a newly appointed VP of Revenue, alongside expansion into PSMA PET/CT AI for prostate cancer and Dosimetry-as-a-Service offerings through the TeleDaas PLLC partnership.

Mirada Medical firmographics

Firmographics
Name
Mirada Medical
Legal name
Mirada Medical Limited
Website
https://mirada-medical.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Mirada Medical is an Oxford-based, privately held medical imaging software company that develops FDA-cleared AI-enabled image registration, auto-contouring, and dosimetry tools sold to hospitals, cancer centers, and OEM imaging partners for cancer diagnosis and radiotherapy planning.
Ownership category
akta.pro rank

Mirada Medical industry classification

Industry
Product category
Medical Imaging Software
NAICS
Software Publishers (5132), Software Publishers (51321)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAJ
Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Medical imaging software
  • Radiation oncology software
  • AI autocontouring
  • Diagnostic imaging solutions
  • Image registration technology

Where Mirada Medical is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Mirada Medical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Imaging Software Licenses: Mirada Medical generates revenue primarily through licensing its medical imaging software products including Mirada XD, Mirada RTx, DLCExpert, and Simplicit90Y. Products are sold directly to hospitals and through OEM partners who embed Mirada technology in their platforms.
  2. OEM/Embedded Software Licensing: Mirada provides its technology on an OEM basis to leading healthcare companies including GE, Canon, Philips, Varian, and Boston Scientific. These partnerships embed Mirada's software within partner platforms, generating licensing revenue.
  3. Professional Services and Support: The company provides customer success services including clinical onboarding, in-clinic deployment, and ongoing optimization support. Implementation and training services are part of the customer engagement model.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise hospital licensing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Mirada Medical product offering

Product offering

Core offering

Mirada Medical develops and licenses AI-powered medical imaging software for cancer care across three clinical specialties: diagnostic imaging (Mirada XD for PET/CT, PET/MR, and nuclear medicine reading), radiation oncology (Mirada RTx for image registration and visualization, DLCExpert for AI-powered organ-at-risk autocontouring), and interventional radiology (Simplicit90Y for Y-90 SIRT dosimetry planning). Products are sold directly to hospitals and cancer centers and embedded through OEM partnerships with GE Healthcare, Canon, Philips, Varian, and Boston Scientific.

Product overview

Mirada Medical delivers a unified portfolio of medical imaging software for diagnosis, dosimetry, and image-guided cancer therapy across three specialties: diagnostic imaging, radiation oncology, and interventional radiology. The core product families are Mirada XD (diagnostic imaging software for PET/CT, PET/MR, and nuclear medicine reading), Mirada RTx (radiation oncology image registration and visualization platform), and Simplicit90Y (interventional dosimetry software for Y-90 SIRT). Key AI capabilities include DLCExpert for automated organ-at-risk contouring, RegEngine for deformable image registration, and zero-click automation platforms. Products are available under Mirada's own brand and on an OEM basis through partnerships with GE, Canon, Philips, Boston Scientific, Varian, and other leading healthcare companies. The software integrates with DICOM-compatible systems and PACS infrastructure across thousands of hospitals globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Mirada XD: Integrated vendor-neutral software for diagnostic reading of PET/CT, PET/MR, nuclear medicine, and image fusion.
  • Mirada RTx
  • Simplicit90Y
  • DLCExpert
  • RegEngine

Products and services

  • Mirada XD

Quantifiable outcome

  • 40-60% reduction in contouring time for H&N, breast, and pelvic disease sites
  • +4 more outcomes

Companies that use Mirada Medical

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles1 record

Mirada Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability9 records

Feature6 records

Mirada Medical partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered strategic, core and minor.

  • Leeds Teaching Hospitals NHS TruststrategicStrategic or Co-development Partner · 18 June 2024Clinical partner for £500,000 Innovate UK grant to develop AI-assisted PSMA PET/CT solution for improved prostate cancer diagnosis.
  • Newcastle upon Tyne Hospitals NHS Foundation TruststrategicStrategic or Co-development Partner · 18 June 2024Clinical partner collaborating on PSMA PET/CT AI solution development under Innovate UK Advancing Precision Medicine grant.
  • University Hospitals Bristol and Weston NHS Foundation TruststrategicStrategic or Co-development Partner · 18 June 2024Clinical partner for PSMA PET/CT AI-assisted solution research and development supporting widespread adoption of PSMA PET/CT in the clinic.
  • TeleDaas PLLCstrategicTechnology or Integration · 26 November 2023Dosimetry-as-a-Service medical practice using Mirada's proprietary software to support clinical research organizations in clinical trial design and development of new targeted radiation therapies.
  • RefleXion MedicalstrategicTechnology or Integration · 7 July 2022Non-exclusive worldwide licensing agreement allowing integration of Mirada's RegEngine image registration algorithms into RefleXion X1 treatment planning software for biology-guided radiotherapy (BgRT).
  • GE HealthcarecoreOEM/ Whitelabel/ Licensing PartnerGlobal collaboration to improve outcomes for cancer patients by integrating Mirada's advanced automation and AI technologies to enable faster, more consistent and more precise cancer radiotherapy treatment. Mirada technology embedded in GE Healthcare ecosystem.
  • Boston ScientificcoreStrategic or Co-development PartnerPartnership to develop and commercialize Simplicit90Y, a software product enabling personalization of dosimetry planning for TheraSphere, Boston Scientific's radiation-based cancer treatment using microscopic radioactive glass microspheres.
  • Canon Medical SystemscoreOEM/ Whitelabel/ Licensing PartnerMirada Oncology Fusion product offered through Canon, integrating Mirada's imaging software with Canon's healthcare IT platform for clinical applications.
  • PhilipscoreOEM/ Whitelabel/ Licensing PartnerPartnership integrating Mirada's imaging technology within Philips healthcare solutions. Mirada products available through Philips ecosystem for diagnostic imaging.
  • VariancoreOEM/ Whitelabel/ Licensing PartnerMirada technology available through Varian's radiotherapy platform, enhancing treatment planning capabilities with Mirada's image registration and AI contouring.
  • Change HealthcareminorChannel Partner/ Reseller/ DistributorDistribution partnership making Mirada technology available through Change Healthcare's imaging solutions and customer network.
  • NCIMI (National Consortium of Intelligent Medical Imaging)strategicStrategic or Co-development PartnerCollaboration with Leeds Teaching Hospitals and Alliance Medical Group investigating role of AI and Deep Learning in diagnostic nuclear medicine, particularly for lymphoma detection and reporting.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Mirada Medical competitors and assessment

Company assessment

Direct peers

  • RaySearch Laboratories: Swedish developer of radiation therapy treatment planning software (RayStation) and oncology analytics. Direct competitor to Mirada RTx and DLCExpert, serving the same radiation oncology customer base with overlapping image registration and adaptive planning capabilities.
  • MIM Software: US-based medical imaging software vendor offering multi-modality viewing, deformable registration, and AI-driven contouring (MIM Maestro). Closely comparable to Mirada's diagnostic imaging and radiation oncology workflows and customer base.
  • Brainlab: Private German company providing treatment planning, image-guided surgery and radiotherapy software (Elements). Directly competes with Mirada in radiation oncology planning and image registration, with overlapping hospital and cancer center customers.

Broad incumbents

  • Elekta: Swedish listed vendor of linear accelerators and radiotherapy software (Mosaiq, Elekta ONE). A broader incumbent in radiation oncology that competes with and could substitute Mirada's planning and autocontouring capabilities as part of its integrated portfolio.
  • Varian (a Siemens Healthineers company): Global leader in radiation oncology treatment planning (Eclipse) and Ethos adaptive radiotherapy. Both an OEM partner of Mirada (Varian) and a potential substitute supplier, making it a strategic incumbent in the same category.
  • Accuray: US-listed developer of CyberKnife and TomoTherapy radiation therapy systems with associated planning software. Broader incumbent serving overlapping radiation oncology customers and competing for the same hospital capital budgets.

Emerging players

  • RefleXion Medical: US-based developer of biology-guided radiotherapy (BgRT) systems that licenses Mirada's RegEngine for its X1 platform. Emerging player in adaptive radiotherapy with a partial, partnership-based overlap to Mirada's image registration business.
  • Quibim: Spanish AI imaging analytics company offering quantitative imaging biomarkers for oncology and radiology. Emerging AI-native vendor addressing similar PET/CT, MRI, and oncology quantification workflows as Mirada XD.

Others

  • GE HealthCare: Global medical imaging equipment and healthcare IT vendor and an OEM partner of Mirada. Adjacent incumbent that both distributes Mirada's technology and develops its own AI imaging applications, making it a strategically dual customer-competitor.
  • Philips: Global healthcare technology vendor with diagnostic imaging, PACS, and oncology informatics offerings, and an OEM partner embedding Mirada's technology. Comparable as a broad incumbent and channel partner rather than a direct specialist competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Mirada Medical social profiles

Digital presence

Mirada Medical compliance and trust

Trust signal

Compliance3 records

Mirada Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mirada Medical leadership team

Management profile

Number of profiles

Profiles6 records

Mirada Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mirada Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirada Medical

What does Mirada Medical do?

Mirada Medical develops and licenses AI-powered medical imaging software for cancer care across three clinical specialties: diagnostic imaging (Mirada XD for PET/CT, PET/MR, and nuclear medicine reading), radiation oncology (Mirada RTx for image registration and visualization, DLCExpert for AI-powered organ-at-risk autocontouring), and interventional radiology (Simplicit90Y for Y-90 SIRT dosimetry planning). Products are sold directly to hospitals and cancer centers and embedded through OEM partnerships with GE Healthcare, Canon, Philips, Varian, and Boston Scientific.

Is Mirada Medical a public or private company?

Mirada Medical is a private company. It is classified as private equity controlled and is currently operating.

When was Mirada Medical founded?

Mirada Medical was founded in 1999. It employs 11 to 50 people.

Where is Mirada Medical based?

Mirada Medical is headquartered in Oxford, United Kingdom, in the Europe region.

How does Mirada Medical make money?

Three revenue lines are on record. Medical Imaging Software Licenses are the primary driver. The others are OEM/Embedded Software Licensing and professional Services and Support.

Who are Mirada Medical's main competitors?

Direct peers on record are RaySearch Laboratories, MIM Software and Brainlab. Broad incumbents are Elekta, Varian (a Siemens Healthineers company) and Accuray. Emerging players are RefleXion Medical and Quibim. Others are GE HealthCare and Philips.

Does Mirada Medical have an API?

No public API is recorded for Mirada Medical.

What industry is Mirada Medical in?

Mirada Medical's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACALAD, Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic). Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
London Tech NewsMirada Medical sees record year as it helps fight COVID-19 backlog - London Tech NewsMirada Medical reported record growth over the past year, with 50% more healthcare organizations using its AI cancer treatment software since March 2020. The company has more than doubled subscription revenues and seen a 92% increase in contracted AI patient volumes. It was also selected for two NHS AI in Health and Care Awards.TelecompaperMiranda-Media acquires LMT-InvestMiranda-Media, a Crimea-based affiliate of Rostelecom, acquired Tattelecom's LMT-Invest subsidiary. LMT-Invest holds a licence for providing telecom services in Crimea.News-MedicalMirada Medical announces series of installations of world’s first AI software for cancer treatmentMirada Medical announced further global installations of its DLCExpert AI software for cancer treatment planning at hospitals including Northwestern, City of Hope, and UMC Groningen. The system is in daily use at over 1,400 hospitals, with studies showing up to 77% time savings for some organs.PR NewswireInternationale multidisziplinäre Arbeitsgruppe gibt Empfehlungen für personalisierte HCC-Behandlung mit 90-Y TheraSphere™ herausBTG plc announced the publication of consensus recommendations from an international multidisciplinary working group for personalized treatment of hepatocellular carcinoma (HCC) using TheraSphere™. These guidelines are supported by interim data from the Dosisphere Phase-II study, which demonstrated higher response rates with personalized dosimetry compared to standard methods. The release also highlights the Simplicit90Y software solution developed in collaboration with Mirada Medical Ltd.PhilipsPhilips introduces IntelliSpace Portal 11 at ECR 2019 to support diagnostic confidencePhilips launched IntelliSpace Portal 11 at the 2019 European Congress of Radiology, adding browser-based viewer capabilities and enhanced security. The software supports multimodal imaging workflows and includes a new Nuclear Medicine Viewer by Mirada Medical. It aims to improve diagnostic confidence and workflow efficiency across hospital networks.NanalyzeAn AI Medical Imaging IPO from MaxQMaxQ, an Israeli AI medical imaging startup, filed for an IPO to raise about $8 million. The company has received FDA 510(k) clearance for its Accipio Ix software and plans FDA approval for Accipio Ix in Q4 2018. It also expects approvals for Accipio Dx and Ax in 2019.PR NewswireBTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y™ Dosimetry Software in EuropeBTG plc and Mirada Medical Ltd announced CE Mark certification for Simplicit90Y™, a dosimetry software designed to optimize planning of 90Y selective internal radiation therapy for liver cancer patients. The software simplifies the complex and time-intensive dosimetry planning and post-treatment validation process, enabling more personalized treatment for each patient. The CE Mark certification follows earlier approval in Canada and allows commercialization of the software across European markets.PR NewswireBTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular CarcinomaBTG announced plans to initiate the TARGET study, a multi-centre evaluation of two-compartment dosimetry for 90Y radioembolisation in hepatocellular carcinoma patients. The study will assess correlation between normal tissue absorbed dose and Grade 3 hyperbilirubinemia, with initiation planned for July 2016 after IRB and EC approval.PR NewswireBTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular CarcinomaBTG plc announced plans to initiate the TARGET study, a multi-centre retrospective evaluation of two-compartment dosimetry for 90Y radioembolisation therapy in patients with hepatocellular carcinoma. The study aims to establish a more personalised treatment approach by correlating normal tissue and tumour absorbed doses with clinical outcomes, utilizing software from partner Mirada Medical. BTG intends to launch the study in July 2016 following regulatory approvals in the United States and select countries in Europe and Asia.PR NewswireBTG and MIRADA Collaborate to Develop Dosimetry Software Solutions to Optimise Radioembolisation Therapy in Interventional OncologyBTG and Mirada announced a collaboration to develop dosimetry software for radioembolisation therapy with TheraSphere, aiming to personalize radiation dosing for liver cancer patients. The software is planned for availability in 2016.